China Continuous Glucose Monitoring Devices Market Report: Market Size & Forecast 2026

China represents the world's largest diabetes population, with up to 140 million individuals affected by type 2 diabetes, creating an enormous addressable market for advanced glucose monitoring technologies. While official public statistical agencies rarely isolate CGM-specific market data, available research confirms that China's glucose testing sector has experienced rapid expansion, with continuous glucose monitoring emerging as the fastest-growing sub-segment. The market encompasses minimally invasive and non-invasive sensor technologies, transmitters, mobile applications, and integrated data analytics platforms designed for both clinical and home-based diabetes management.

• •Estimated 140 million people in China live with type 2 diabetes, representing the world's largest patient pool for CGM devices
• •China's total diabetes economic burden is projected to reach $460.4 billion by 2030, driving urgent demand for cost-effective monitoring solutions
• •CGM adoption has grown from a niche clinical tool to a mainstream diabetes management technology within the Chinese healthcare system
• •The broader biosensor and wearable medical device markets are expanding rapidly, supported by aggressive national medical IoT standardization initiatives

The primary growth engine is China's massive and worsening diabetes epidemic, which has made glucose monitoring a national public health priority. Clinical modeling studies demonstrate that continuous glucose monitoring is cost-effective for managing uncontrolled diabetes in Chinese adults, supporting insurance reimbursement and clinical guideline adoption. Additionally, China's aggressive medical IoT standardization and wearable device infrastructure expansion, projected at a regional CAGR of 13.4% through 2036, creates a favorable technological ecosystem for connected CGM systems.

• •Rising prevalence of diabetes among Chinese adults, coupled with growing awareness of complications prevention through real-time monitoring
• •Cost-effectiveness evidence supporting CGM adoption in clinical practice, driving physician recommendation and patient demand
• •Government backing for domestic medical technology manufacturing and digital health infrastructure development
• •Advancements in nanobiosensing and sensor accuracy, making CGM systems more reliable and accessible for Chinese clinical settings

The China CGM market is segmented by technology type, including real-time CGM (rtCGM), flash glucose monitoring (FGM), and implantable systems, as well as by end-user, spanning hospital-based diabetes centers, specialty clinics, and direct-to-consumer channels. Geographically, tier-1 cities like Beijing, Shanghai, and Guangzhou account for the highest adoption rates due to greater healthcare access, higher disposable incomes, and earlier regulatory approvals for advanced medical devices. Tier-2 and tier-3 cities are experiencing accelerating growth as insurance coverage expands and local manufacturing reduces product costs.

• •Real-time CGM and flash glucose monitoring dominate market share, with rtCGM preferred in hospital settings and FGM gaining traction among outpatients
• •Tier-1 urban centers lead adoption, but tier-2 and tier-3 cities represent the highest growth potential as healthcare infrastructure improves
• •Domestic and international products coexist, with local manufacturers offering more affordable options to price-sensitive consumers
• •Hospital pharmacies and diabetes specialty clinics remain the primary distribution channels, though e-commerce and D2C platforms are growing

What are the recent trends and outlook?

The China CGM market is expected to sustain its double-digit growth trajectory through 2030, supported by ongoing diabetes awareness campaigns, expanding insurance coverage, and integration with digital health platforms. Connectivity and data interoperability are emerging as critical differentiators, as Chinese consumers increasingly demand seamless integration with smartphones and health management ecosystems. Additionally, the market is witnessing a shift toward smaller, longer-lasting sensors and the incorporation of artificial intelligence for predictive glucose analytics, aligning with China's broader smart healthcare initiatives.

• •Integration with wearable health ecosystems and telehealth platforms is expected to drive next-generation CGM product development
• •Longer sensor wear durations (14-day and beyond) and improved accuracy are becoming key competitive benchmarks
• •Government health digitization policies are encouraging data-driven diabetes management solutions, creating opportunities for connected CGM platforms
• •Price erosion from domestic manufacturing competition is likely to broaden CGM accessibility across income segments and geographic regions